Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
Clinical trials show a pancreatic cancer drug nearly doubles survival, a head-and-neck therapy shrinks tumors, and new research explains drug resistance. Cancer mortality is falling in the US and UK.
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780968 |
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA |
NOT_YET_RECRUITING | |
| NCT07653594 |
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) |
NOT_YET_RECRUITING | NA |
| NCT07578571 |
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer |
RECRUITING | PHASE1 |
| NCT07540169 |
The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer |
COMPLETED | NA |
| NCT05415475 |
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors |
COMPLETED | PHASE1 |
| NCT03030404 |
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer |
COMPLETED |
